Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Prelude Therapeutics Inc (PRLD) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update",
"Presentation"
03/15/2023 8-K Quarterly results
Docs: "Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update Four differentiated clinical compounds progressing through Phase 1 towards key data milestones Eight abstracts accepted for presentation at the 2023 American Association for Cancer Research Annual Meeting Cash balance of $201.7 million as of December 31, 2022; runway remains unchanged through Q4 2024 Wilmington, DE – March 15, 2023 –",
"D ENGINE DIFFERENTIATED PROGRAMS APPROACH CDK9 MCL1 SMARCA2 CDK4/6",
"Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers WILMINGTON, Del. – March 15, 2023 –"
11/14/2022 8-K Quarterly results
Docs: "Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update FDA clearance of two new INDs: PRT3789 and PRT3645 Company to reprioritize clinical pipeline and discontinue PRMT5 program for internal development Strong cash, cash equivalents and marketable securities of $224.0 million as of September 30, 2022, expected to fund multiple data catalysts with a runway into the fourth quarter of 2024 WILMINGTON, Del.",
"PRT543, PRT811, PRT1419, PRT2527, PRT3645, PRT3789"
08/09/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/16/2022 8-K Quarterly results
Docs: "Prelude Therapeutics Reports Full Year 2021 Financial Results Significant progress achieved in 2021: Pipeline now includes six internally discovered small molecule compounds targeting clinically validated pathways in cancers with underserved patients"
11/12/2021 8-K Quarterly results
Docs: "Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update PRT543 and PRT811 Demonstrate Favorable Safety Profile, Tolerability and Evidence of Preliminary Clinical Activity in Phase 1 Dose Escalation in Unselected Patients",
"Presentation"
08/12/2021 8-K Quarterly results
05/11/2021 8-K Quarterly results
03/16/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "Prelude Therapeutics Announces Third Quarter 2020 Financial Results - Completed Initial Public Offering of Common Stock, Raising Gross Proceeds of ~$181.9M million -"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy